[Robert G. Atkinson, James W. Kelly, Jr., Bryan W. Tuttle, Robert M. Price, Robert P. Reichel] ,Woodinville,WA,;,Redmond,WA,;,Newcastle,WA,;,Seattle,WA,;,Redmond,WA, A certification or signature is incorporated in a computer program, an executable file, or code to assure its authenticity and integrity, particularly for receiving it over an open computer network like the Internet. The executable file may be of any executable form, including an executable or portable executable .exe file format, a .cab cabinet file format, an .ocx object control format, or a Java class file. The certification includes a keyed source confirmation with a secure representation of the executable file. In an embodiment, the certification is referenced in a header of the executable file, the reference including a pointer to the keyed source confirmation and an indication of the size of the keyed source confirmation.

[ATKINS, Robert, Charles, CHADBAN, Steven, James, COOPER, Mark, Emmanuel, GILBERT, Richard, Ernest, HILL, Prudence, Ann, KELLY, Darren, James, NIKOLIC-PATERSON, David, John] Lichtstrasse 35, 4056 Basel, CH

[NIKOLIC-PATERSON DAVID JOHN, KELLY DARREN JAMES, HILL PRUDENCE ANN, GILBERT RICHARD ERNEST, COOPER MARK EMMANUEL, CHADBAN STEVEN JAMES, ATKINS ROBERT CHARLES] AU;AU;AU;AU;AU;AU;AU;AU;AU

[ATKINS ROBERT CHARLES, CHADBAN STEVEN JAMES, COOPER MARK EMMANUEL, GILBERT RICHARD ERNEST, HILL PRUDENCE ANN, KELLY DARREN JAMES, NIKOLIC-PATERSON DAVID JOHN] ;;;;;;;;; The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R<SUB>1 </SUB>is pyridyl bonded at a carbon atom, R<SUB>2</SUB>, R<SUB>3</SUB>, R<SUB>5</SUB>, R<SUB>6 </SUB>and R<SUB>8 </SUB>are each hydrogen, R<SUB>4 </SUB>is lower alkyl, R<SUB>7 </SUB>a radical of formula (II): -N(R<SUB>9</SUB>)-C(-X)-(Y)<SUB>n</SUB>-R<SUB>10</SUB>, wherein R<SUB>9 </SUB>hydrogen, X is oxo, n is 0 and R<SUB>10 </SUB>is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

[ATKINS ROBERT, CHADBAN STEVEN, COOPER MARK, GILBERT RICHARD, HILL PRUDENCE, KELLY DARREN, NIKOLIC-PATERSON DAVID] AU;AU;AU;AU;AU;AU;AU;AU;AT The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R<SUB>1 </SUB>is pyridyl bonded at a carbon atom, R<SUB>2</SUB>, R<SUB>3</SUB>, R<SUB>5</SUB>, R<SUB>6 </SUB>and R<SUB>8 </SUB>are each hydrogen, R<SUB>4 </SUB>is lower alkyl, R<SUB>7 </SUB>a radical of formula (II): -N(R<SUB>9</SUB>)-C(-X)-(Y)<SUB>n</SUB>-R<SUB>10</SUB>, wherein R<SUB>9 </SUB>hydrogen, X is oxo, n is 0 and R<SUB>10 </SUB>is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

[ATKINS ROBERT CHARLES, CHADBAN STEVEN JAMES, COOPER MARK EMMANUEL, GILBERT RICHARD ERNEST, HILL PRUDENCE ANN, KELLY DARREN JAMES, NIKOLIC-PATERSON DAVID JOHN] AU;AU;AU;AU;AU;AU;AU;AU;CH;AU

[Lee James Beeley, Kelly Paine, Robert James Godden] GB Dorking HNFCW60 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HNFCW60 polypeptides and polynucleotides in the design of protocols for the treatment of obesity, diabetes, hyperlipademia and body weight disorder, among others, and diagnostic assays for such conditions.

[Loren B. Sheldon, James R. Tomashek, Robert R. Kelly, James S. Thale, Jashwant C. Shah, Donald H. Ward] TX Houston 8226 Bairnsdale 77070 In a hydraulically powered pipe handling system, a general purpose digital computer is used to control the operation of hydraulically powered racker arms as well as the various auxiliary functions involved in vertical piperacking operations. The manual pipe-racking system (that is, that which is hydraulically powered and under the control of one or more operators) is retained, the computer controlled mode of operation being an alternative system present in the overall design.There is provided to the operator, while the system is in its automatic mode of operation, visual indication of length of drill string, depth of hole, depth of drill bit and composition of the drill string, including number and type of pipe lengths making up the drill string.

[ATKINS, Robert, Charles, CHADBAN, Steven, James, COOPER, Mark, Emmanuel, GILBERT, Richard, Ernest, HILL, Prudence, Ann, KELLY, Darren, James, NIKOLIC-PATERSON, David, John] Lichtstrasse 35 CH-4056 Basel;7 Wentworth Avenue Canterbury, VIC 3126;73 Ardoyne Street Blackrock, VIC 3193;50 Molesworth Street Kew, VIC 3101;16 Mary Street West St. Kilda, VIC 3182;7 Wentworth Avenue Canterbury, VIC 3126;1 Commerford Place Chirnside Village, VIC 3116;170 Mt. Grantview Road Pearcedale, VIC 3912;Parkville, VIC 3052;Monash Medical Center 246 Clayton Road Clayton, VIC 3168 The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1, is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II):-N(R9)-C(=X)-(Y)n-R10, wherein R9 is hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

[ATKINS, Robert, Charles, CHADBAN, Steven, James, COOPER, Mark, Emmanuel, GILBERT, Richard, Ernest, HILL, Prudence, Ann, KELLY, Darren, James, NIKOLIC-PATERSON, David, John] Lichtstrasse 35, 4056 Basel, CH